PA
CE

Certara

Biosimulation leader accelerating safer, faster drug development from discovery to market access.

Visit Website

Known For

Global leader in biosimulation/MIDD with 90%+ FDA novel approvals supported

Key Differentiators

  • Global leader in biosimulation/MIDD with 90%+ FDA novel approvals supported
  • integrated software-services ecosystem across full drug lifecycle
  • regulatory-qualified tools used by FDA/EMA in evaluations.

Overview

Certara provides biosimulation software, technology-driven services, and consulting to accelerate drug discovery, development, regulatory approval, and market access for biopharma companies. Using model-informed drug development (MIDD), pharmacometrics, PBPK/QSP modeling, and AI tools, they optimize dosing, trial design, and submissions across all phases. Their solutions have supported 90%+ of FDA novel drug approvals since 2014.

Services & Capabilities

  • Biosimulation software (Simcyp PBPK, Phoenix PK/PD)
  • pharmacometrics & QSP consulting
  • regulatory writing & submissions
  • clinical trial design & biostatistics
  • market access & HEOR
  • drug development strategy (preclinical to commercial)
  • AI platforms (Certara.AI, D360).

Competitive Position

  • Global leader in biosimulation/MIDD with 90%+ FDA novel approvals supported
  • integrated software-services ecosystem across full drug lifecycle
  • regulatory-qualified tools used by FDA/EMA in evaluations.

Recent Developments

2024: Completed acquisition of Chemaxon. 2025: Q3 revenue $104.6M (+10%). 2026: New CEO Jon Resnick (Jan 2026); FY2025 revenue $418.8M (+9%); FY2026 guidance flat to +4% revenue.

Client & Partner Ecosystem

Biohaven (Nurtec), Dizal (Sunvozertinib), Biogen, Arvinas, Prelude Therapeutics, Charles River, Veeva Certara website, LinkedIn, ; Biohaven Pharmaceuticals (Nurtec ODT)

Technology Platform

Simcyp, Phoenix, Certara.AI, D360, GlobalSubmit; Simcyp Simulator

Therapeutic Focus

broad/all (oncology, rare disease, cell & gene therapy, vaccines, biologics, pediatrics)

Target Customers

biopharmaceutical companies, academic institutions, regulatory agencies

Sources